Therapeutic approaches to patients with hypereosinophilic syndromes

Simon, Hans-Uwe; Klion, Amy (2012). Therapeutic approaches to patients with hypereosinophilic syndromes. Seminars in hematology, 49(2), pp. 160-70. Philadelphia, Pa.: W.B. Saunders 10.1053/j.seminhematol.2012.01.002

Full text not available from this repository. (Request a copy)

Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders that range from asymptomatic eosinophilia > 1,500/mL to aggressive disease complicated by life-threatening end organ involvement, including endomyocardial fibrosis and thromboembolism. To complicate matters further, similar clinical manifestations can occur in the setting of marked eosinophilia due to helminth infection, drug hypersensitivity, and other causes. In the past, therapy was guided only by the exclusion of these secondary causes of eosinophilia and the severity of the clinical manifestations. More recently, the availability of novel targeted therapies and a better understanding of the etiologies of some subtypes of HES have necessitated a more structured approach.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe




W.B. Saunders




Factscience Import

Date Deposited:

04 Oct 2013 14:35

Last Modified:

05 Dec 2022 14:11

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 220919)

Actions (login required)

Edit item Edit item
Provide Feedback